Leerink Partnrs Has Bullish Forecast for EWTX Q1 Earnings

Edgewise Therapeutics, Inc. (NASDAQ:EWTX) – Leerink Partnrs lifted their Q1 2025 earnings per share estimates for Edgewise Therapeutics in a report released on Wednesday, April 2nd. Leerink Partnrs analyst J. Schwartz now expects that the company will post earnings of ($0.44) per share for the quarter, up from their previous estimate of ($0.45). The consensus estimate for Edgewise Therapeutics’ current full-year earnings is ($1.45) per share. Leerink Partnrs also issued estimates for Edgewise Therapeutics’ Q2 2025 earnings at ($0.49) EPS, Q3 2025 earnings at ($0.51) EPS, Q4 2025 earnings at ($0.55) EPS, FY2025 earnings at ($2.00) EPS and FY2026 earnings at ($1.95) EPS.

Edgewise Therapeutics (NASDAQ:EWTX) last released its earnings results on Monday, March 3rd. The company reported ($0.42) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.03).

EWTX has been the topic of a number of other reports. Scotiabank lowered shares of Edgewise Therapeutics from a “sector outperform” rating to a “sector perform” rating and decreased their target price for the stock from $50.00 to $14.00 in a research note on Wednesday, April 2nd. Piper Sandler reiterated an “overweight” rating and set a $51.00 price objective on shares of Edgewise Therapeutics in a research report on Wednesday, April 2nd. Stifel Nicolaus began coverage on Edgewise Therapeutics in a research note on Wednesday, January 22nd. They set a “hold” rating and a $30.00 price objective on the stock. Royal Bank of Canada cut their target price on Edgewise Therapeutics from $56.00 to $52.00 and set an “outperform” rating for the company in a research note on Thursday, April 3rd. Finally, Evercore ISI lifted their price target on Edgewise Therapeutics from $45.00 to $50.00 and gave the stock an “outperform” rating in a report on Tuesday, December 17th. Two research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $40.38.

Edgewise Therapeutics Trading Up 2.8 %

EWTX opened at $11.83 on Monday. Edgewise Therapeutics has a twelve month low of $10.60 and a twelve month high of $38.12. The firm has a market capitalization of $1.24 billion, a PE ratio of -7.89 and a beta of 0.32. The firm’s 50-day moving average price is $24.88 and its 200 day moving average price is $28.42.

Hedge Funds Weigh In On Edgewise Therapeutics

Several institutional investors have recently bought and sold shares of the company. Paradigm Biocapital Advisors LP increased its position in shares of Edgewise Therapeutics by 61.1% during the fourth quarter. Paradigm Biocapital Advisors LP now owns 4,493,929 shares of the company’s stock worth $119,988,000 after acquiring an additional 1,704,757 shares during the period. First Light Asset Management LLC purchased a new stake in Edgewise Therapeutics during the 4th quarter worth about $20,843,000. Foresite Capital Management VI LLC acquired a new position in shares of Edgewise Therapeutics during the 4th quarter worth about $15,620,000. Janus Henderson Group PLC increased its holdings in shares of Edgewise Therapeutics by 9.3% in the 4th quarter. Janus Henderson Group PLC now owns 4,983,940 shares of the company’s stock valued at $133,044,000 after acquiring an additional 425,421 shares during the last quarter. Finally, Braidwell LP raised its position in shares of Edgewise Therapeutics by 19.1% during the 4th quarter. Braidwell LP now owns 2,332,196 shares of the company’s stock worth $62,270,000 after acquiring an additional 373,886 shares in the last quarter.

Insiders Place Their Bets

In other news, CMO Joanne M. Donovan sold 25,000 shares of the company’s stock in a transaction that occurred on Tuesday, January 28th. The shares were sold at an average price of $27.63, for a total value of $690,750.00. Following the transaction, the chief marketing officer now directly owns 16,358 shares in the company, valued at approximately $451,971.54. This represents a 60.45 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Orbimed Advisors Llc purchased 496,771 shares of the stock in a transaction dated Thursday, April 3rd. The shares were purchased at an average price of $20.13 per share, with a total value of $10,000,000.23. Following the completion of the transaction, the director now owns 14,809,075 shares of the company’s stock, valued at approximately $298,106,679.75. This trade represents a 3.47 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders sold a total of 34,836 shares of company stock valued at $986,245 over the last quarter. 24.11% of the stock is owned by insiders.

About Edgewise Therapeutics

Edgewise Therapeutics, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy.